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The effect of radiosensitizers on the pharmacokinetics of
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Summary Misonidazole (MISO) has been shown to affect the pharmacokinetics of both cyclophosphamide
(CY) and melphalan (MEL) in WHT mice resulting in increased plasma levels of the cytotoxic drugs. The
effect is not solely due to the reduction in body temperature observed with large single doses of MISO, as a
change in MEL pharmacokinetics was still observed when the mice were maintained at 37°C. Inhibition of
cytotoxic drug metabolism may also be a possible mechanism. Such a pharmacokinetic effect could account
for part of the potentiation of MEL and CY action observed in tumours with large single doses of MISO.
However, a chronic low dosing schedule of MISO did not affect the plasma half-life of either cytotoxic drug,
although a significant potentiation of each drug in combination with a chronic MISO dose has been obtained
in some tumours. These results suggest that potentiation of chemotherapeutic drug action by MISO in the
clinical situation is unlikely to be due to changes in drug pharmacokinetics.
Introduction
The 2-nitroimidazole radiosensitizer misonidasole
(MISO) can significantly enhance the response of
tumours to several chemotherapeutic drugs
particularly at high doses (see review by McNally
(1982)). Although several mechanisms have been
postulated (Brown, 1982) the nature of the main
ones responsible for this enhancement remain
unclear. One possible explanation is that the
radiosensitizer may alter the pharmacokinetics of
the cytotoxic drug possibly in a way which would
effectively increase the tissue exposure to the drug.
We have therefore investigated the effects of
MISO on the pharmacokinetics of melphalan
(MEL) and cyclophosphamide (CY) in order to try
and determine the extent to which alteration in
drug pharmacokinetics might contribute to the
enhancement observed when a large single dose of
MISO is given in combination with these agents. In
addition, we have investigated the effect of chronic
low doses of MISO given in a regime which more
closely simulates human pharmacokinetics.
Materials and methods
Mice
WHT/GyfBSVS male mice between 3 and 4 months
old, maintained in Category 4 specific pathogen-
free conditions were used in all procedures. In two
B.J.C.-C
of the CY experiments female WHT mice (ex
breeders) between 3 and 6 months old were used.
They were not used in later experiments because it
was subsequently found that older WHT mice
suffer from a congenital kidney dysfunction.
Measurement ofmelphalan plasma levels
Blood was obtained from the carotid artery after
decapitation. Blood samples were collected in
heparinised tubes, immediately cooled on ice and
then centrifuged as soon as possible at 4°C. An
aliquot of plasma was taken, frozen rapidly and
stored at -20°C for subsequent analysis. Plasma
was deproteinised with 2 volumes of methanol,
cooled to -70°C to aid precipitation, centrifuged
and the supernatant analysed for MEL by high
performance liquid chromatography (HPLC).
Chromatography was carried out using an LDC
constametric pump, Waters WISP Autosampler, a
Hypersil 5 ODS column and a Waters 441 uV
detector operating at 254 nm; the results were
presented and calculated on a Waters 730 data
module calibrated against plasma samples
containing a known concentration of MEL. The
standard solution of MEL was prepared in
methanol containing 2% acetic acid (Chang et al.,
1978). The eluant was 63% methanol; 5mM
heptane sulphonic acid, 2mM% dibutylamine,
10mM acetic acid, pumped at 2mlmin- 1
.
Measurement ofcyclophosphamide plasma levels
An estimate of the concentration of active
metabolites of CY in the blood at varying times
after treatment was obtained using a modification
of the tissue culture cytotoxicity assay first outlined
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by Weaver et al. (1978) and developed in this
laboratory by Begg & Smith (in preparation).
Blood was taken from the mice at varying times
after i.p. injection of 200mgkg-' CY with or
without MISO. The brachial artery was cut in
lightly anaesthetised mice and blood drawn up into
a heparinsed syringe. The mice were then sacrificed
without regaining consciousness. Blood pooled
from 4-5 mice was kept on ice until it could be
centrifuged. The serum was then removed, sterilised
by filtration and diluted 1:20 in complete tissue
culture medium (alpha-MEM plus 10% foetal calf
serum). Two ml of the diluted "activated" CY was
then added to V79 Chinese hamster cells plated
several hours previously in 5 cm diameter Petri
dishes. After incubating with the serum for 15h, the
plates were rinsed twice with Hanks' balanced salt
solution and 5ml of fresh medium added. Cell
survival was estimated by counting the resulting
colonies after incubating for 7 days at 37°C.
Control plates received diluted serum from
untreated mice.
Radiosensitizers
For the acute doses 800mgkg-1 (4mmolkg-1)
MISO was dissolved in saline at a concentration
such that a 40 g mouse would receive 1 ml, and
injected i.p. In the chronic dose schedules
120mgkg-t was injected i.p. followed by
30mgkg-1 every 20min for 8h in order to
maintain a plasma concentration of 100 ugml-'
over this period. This simulated the long half-life of
MISO in man. For the chronic doses the drug was
diluted so that a 40g mouse would receive 0.2ml.
The cytotoxic drug was given immediately after the
last dose of MISO. Mice treated with the cytotoxic
drug alone received corresponding volumes of saline
in both chronic and acute dose regimes. The radio-
sensitizer SR-2508 was administered by i.v. injection
at a dose of 1070mgkg-1 (5mmolkg-') at a
concentration such that a 40g mouse would receive
0.4ml.
Cytotoxic drugs
MEL was first dissolved in 0.5ml 2% HCl in
ethanol, then further diluted in saline. For phar-
macokinetic studies, 10mgkg-1 was injected i.p. at
a concentration of 0.4ml per 40 g mouse within
10min of dissolution. CY at a dose of 200mgkg-'
was injected i.p. dissolved in saline. As with MEL
the concentration was such that a 40 g mouse
received 0.4ml. Linear regression analysis was used
to calculate the "best fit" lines through the
pharmacokinetics data for MEL. Drug half-lives
were calculated from these lines, the errors given
representing +ls.d.
Results
Figure 1(a) shows the plasma concentrations of
MEL as a function of time after i.p. injections,
either alone or 15min after MISO at a dose of
800mgkg- . In this and subsequent figures for
MEL each point represents an individual mouse.
Open symbols represent MEL alone and closed
symbols represent combination of MISO with
MEL. Different shapes are used to represent
separate experiments. Because MEL is rapidly
hydrolysed in aqueous solution at room
temperature, MISO was given before rather than at
the same time as MEL in order for the MEL to be
injected as quickly as possible. MISO affected the
pharmocokinetics of MEL in that it appeared to
cause an extension of the peak concentration and a
subsequent decrease in the rate of plasma clearance.
The MEL plasma half-life was extended from 21
(19.5-21.5) to 50 (44.5-56.5) min. When MISO was
given an hour before MEL (Figure l(b)) there was
a reduced effect on the rate of plasma clearance,
T1/2=34min (32-36), but the plasma concentration
remained at its maximum level for up to 40min.
Both Figures l(a) and l(b) are composites of 2
separate experiments.
Figure 2 shows the rate of decay of "active" CY
metabolites in plasma in the presence or absence of
MISO given simultaneously with (Figure 2(a)), or
1 h before CY (Figure 2(b)). In this and subsequent
figures for CY each point represents the effect of
serum pooled from 4-5 mice. An indication of the
concentration of active CY metabolites in the
plasma at a given time after injection was obtained
indirectly by determining the toxicity of serum to
V79 cells as described above. There was no effect of
serum from untreated mice. Again MISO appeared
to affect the pharmocokinetics of CY. The
displacement of the curves with MISO relative to
the controls indicates a retention of active CY
metabolites in the plasma. There was some inter-
experimental variation in the degree of cell killing
obtained, particularly in the first 30min after
injection when plasma CY concentrations were
changing rapidly. However, the displacement of the
curves at times beyond 30min did not vary between
experiments.
It is possible that the in vitro interaction of
MISO metabolites with activated CY was
responsible for the decrease in V79 cell survival
seen for the combined treatment, rather than a
retention of active CY metabolites in the plasma.
Serum from mice receiving MISO alone was
therefore combined with that from mice receiving
CY alone and added to V79 cells in vitro. Blood
samples from both MISO and CY treated mice
were taken at the same times after the injection of
each drug to ensure, as far as possible, that bothRADIOSENSITIZERS AND THE PHARMACOKINETICS OF CYTOTOXIC DRUGS
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Figure 1 Plasma levels of MEL in WHT mice after lOmgkg-' MEL alone (O, A, OL), or lOmgkg-' MEL
plus 800mgkg-' MISO (0, A, U). (a) MISO-15min-MEL; (b) MISO-lh-MEL. Different symbols
refer to separate experiments, each point represents an individual mouse. In this, and subsequent figures for
MEL, lines of "best fit" were determined by linear regression analysis. Points occuring before the plasma
clearance phase commenced were omitted from the analysis.
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Figure 2 Survival of V79 cells after treatment with plasma from WHT mice receiving 200mgkg-' CY along
(0), or 200mgkg-' CY plus 800mgkg-' MISO (0). (a) MISO and CY given simultaneously; (b) MISO-
1 h-Cy. Each point represents the mean surviving fraction from four replicate plates having received diluted
serum pooled from 4-5 mice.
drugs had been metabolised to the same extent as if
given simultaneously to the same mouse. The
resulting survival curves are shown in Figure 3.
There was no effect of mixing "activated" MISO
with "activated" CY in vitro. In the same
experiment MISO and CY were given together to a
group of mice and Figure 3 shows that, as before
(Figure 2) the clearance of "active" metabolites
appeared to be delayed.
A large single dose of MISO (800mgkg- 1,
4mmolkg-1) administered to mice at room
temperatures caused a reduction in rectal
temperature of 5°C (Figure 4(a)). This lowered
temperature was reached within an hour of
injection and was maintained for a further 4h. The
combination of this dose of MISO with CY
(200mgkg'I injected 60min after MISO) caused a
further reduction in temperature of 3-40C (total
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Figure 3 Survival of V79 cells after treatment with
plasma from WHT mice receiving 200mgkg- CY
alone (O), 200mgkg-' CY plus 800mgkg-1 MISO
given simultaneously (@), 200mgkg-1 CY or
800mgkg-' MISO and mixed in vitro (A), (see text)
or 800mgkg-t. MISO alone (U). Each point
represents the mean surviving fraction from 4 replicate
plates having received diluted serum pooled from 4-5
mice.
reduction, 9°C). This was maintained for at least
5 h and still appeared to be falling at the end of this
period. Combination of MEL with MISO caused a
total temperature reduction of 6°C (data not
shown). If the mice were maintained at an ambient
temperature of 37°C there was no significant fall in
rectal temperature (Figure 4(b)) due to the MISO.
However, the combination of MISO and CY then
proved toxic to these mice. Mice receiving this
combined treatment died between 1 and 4h after
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receiving MISO, so that it was not possible to
make pharmacokinetic measurements.
The effect of MISO on MEL pharmacokinetics
was investigated when the mice were maintained in
an ambient temperature of 37°C (Figure 5). This
combination proved less toxic and the mice
survived the duration of the experiment. Rectal
temperatures were measured throughout the
experiment and were not observed to drop with
either MEL alone or the combination treatment. A
change in MEL pharmacokinetics was still observed
(Figure 5), although it was reduced compared to
that at room temperature. MISO still appeared to
prolong the peak plasma concentration at this
temperature, but only a very small increase in the
plasma half-life was observed from 21+1.5min to
27+2min, which may not be significant.
The nitroimidazole radiosensitizer SR-2508,
unlike MISO, is not metabolised in the mouse
(Workman & Brown 1981) and does not reduce
body temperature; however, it has been found to
potentiate the action of CY in the RIF-1 tumour
(Law et al., 1981). We therefore investigated the
effect of SR-2508 on MEL pharmacokinetics. A
dose of 1070mgkg-1 (5mmolkg-1) SR-2508 had
no effect on the plasma half-life of MEL when
injected 30min before MEL (Figure 6). SR-2508
was injected 30min rather than an hour before
MEL, because ofits shorter half-life in the mouse of
45-50min for a dose of 5mmolkg-' compared to
80-100min for an equivalent MISO dose.
The effect of a chronic dosing schedule of MISO
was also examined. A plasma concentration of
100pgml-1 (0.5mM) MISO was maintained for 8h
prior to giving the cytotoxic drug in an attempt to
simulate the extended plasma half-life of MISO in
man compared to that in mice. This is close to the
plasma level which would be reached in man during
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Figure 4 Mouse rectal temperatures after 200mgkg-1 CY alone ( - * -- -), 800mgkg-'MISO-1 h-CY (----)
or, no treatment ( ). (a) at room temperature (20°C); (b) at 37°C. Each line represents one mouse.
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Figure 5 Plasma levels of MEL in WHT mice
maintained at 37°C after lOmgkg-1 MEL alone (0,
El) or l0mgkg-' MEL plus 800mgkg-1 MISO (0,
*). Circles and squares represent 2 separate
experiments, each point represents an individual
mouse. Lines of "best fit" were obtained by linear
regression analysis, as previously described.
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Figure 6 Plasma levels of MEL in WHT mice after
l0mgkg-' MEL only (A) or l040mgkg-1 SR-2508
30min before l0mgkg-1 MEL (A). Each point
represents an individual mouse. The "line of best fit"
was obtained by linear regression analysis, as
previously described.
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Figure 7 Plasma levels of MEL in WHT mice
receiving 10mgkg-1 MEL immediately after an 8h
chronic dose of saline (O), or of MISO (0). Each
point represents one mouse. The line of "best fit" was
obtained by linear regression analysis, as described
previously.
a standard 6 fraction regime where 2gm-2 were
administered each time.
The chronic dose schedule had no effect on the
mouse body temperature and the plasma half-life of
MEL was not altered when a dose of 10mgkg-1
was given at the end of the chronic MISO dosing
(Figure 7). Similarly, the amount of active CY
metabolites was not affected when a dose of
200mgkg-' was given with the last MISO injection
(Figure 8).
Discussion
A large single dose of MISO (800mgkg-1) had a
considerable effect on the pharmacokinetics of
MEL (Figures l(a) and (b)), prolonging the peak
concentration of MEL and delaying its subsequent
plasma clearance. The effect varied according to the
interval between the administration of the two
drugs. When MISO was given 15min before MEL
(Figure 1(a)) there was a pronounced delay in the
plasma clearance rate, and the MEL T112 was
increased from 20 (19.5-21.5) to 50 (44.5-56.5) min.
However, when MISO was given an hour before
MEL (Figure 1(b)), which is the usual interval used
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Figure 8 Survivial of V79 cells after treatment with
plasma from WHT mice receiving 200mgkg-' CY
immediately after an 8h chronic dose of saline (0, [1),
or of MISO (0, *). Each point represents the mean
surviving fraction from four replicate plates having
received diluted serum pooled from 4-5 mice.
in our tumour studies (McNally et al., 1983) there
was a reduced effect on the rate of plasma
clearance, T,2 =34min (32-36) but this was
compensated by an increased retention of the peak
plasma concentration. In both instances, the
combined effects resulted in similar raised levels of
MEL in the plasma at any given time after
injection.
The results of the bioassay for CY indicate that
MISO also delayed the clearance of active CY
metabolites from the plasma (Figure 2). There was
no noticeable difference between giving the MISO
at the same time as CY (Figure 2(a)) or 1 h before
(Figure 2(b)). However, any difference at early
times were unlikely to be detected with the assay
used (see above). Using a similar assay, Tannock
(1980) has demonstrated retention of active CY
metabolites in the serum of C3H mice after
receiving 1000mgkg-' (5mmolkg-1) MISO. An
increase in the plasma half-life of MEL with a large
single dose of MISO has been reported by several
otherinvestigators (Stephens etal., 1981; Clutterbuck,
1982; Lee & Workman, 1983). Similar effects have
also been observed with BCNU (Tannock, 1980)
and CCNU (Lee & Workman, 1983).
The same large dose of MISO as used in the
present studies gave enhancement ratios (ERs) of
2.7. and 1.8 for MEL and CY respectively in the
WHFIB tumour using a cell cloning assay
(McNally et al., 1983). It is possible that an
alteration of drug pharmacokinetics could account
for a significant proportion of this chemosensi-
tization observed with large single doses of MISO.
The existence of a large pharmacokinetic
component of the interaction has previously been
disputed on the grounds that it would not account
for the large "therapeutic gains" observed by
ourselves and other investigators (McNally, 1982)
as more drug will be made available to both
tumours and normal tissues. However, it is possible
that prolonged exposure would lead to more drug
being available to the tumour without a
corresponding increase in normal tissue
concentration. For example, Lee & Workman
(1983) observed increased concentrations of CCNU
in tumours relative to normal tissues, when
combined with large doses of MISO.
Two possible mechanisms whereby MISO could
affect drug pharmacokinetics are a reduction in
mouse core temperature and/or inhibition of drug
metabolism by MISO.
Reduction in core temperature
A dose of 800mgkg-' (4molkg-') MISO caused a
reduction in body temperature of about 5°C which
was maintained for 4h (Figure 4(a)), well beyond
the longest time at which drug plasma
concentrations were measured. Similar temperature
effects have been reported by Law et al. (1981) and
Twentyman & Workman (1982). The latter
investigators have shown that this reduced
temperature persists for 10-12h. In our experiments
addition of 200mgkg-' CY 60min after MISO
further reduced mouse rectal temperature by about
3°C (total reduction 9°C), whilst addition of
10mgkg-' MEL caused a total reduction of 60C
(results not shown).
The difference in MEL pharmacokinetics when
given 15 or 60min after MISO (Figures l(a) and
1(b)) is difficult to explain. However it may be
related to differences in the reduction of body
temperature due to MISO at the two times; at
15min the temperature had only fallen by 2°C,
whereas the total reduction by 6°C was complete at
60min. This increased reduction in temperature at
60min may result in a decrease in the apparent
volume of distribution which could be expected to
cause either an increase in or extension of the peak
plasma concentration of MEL. However, the same
extension in the peak MEL concentrations was
observed when the mice were maintained at 370C
(Figure 5), so that while there was no decrease in
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the rate of plasma clearance at this temperature, a
significant increase in the MEL "area under the
curve" was still obtained. Clearly a reduction in
body temperature is not a sufficient explanation for
the alteration of MEL pharmocokinetics due to
MISO. Lee & Workman (1983) have also
demonstrated changes in drug pharmacokinetics (in
this case with CCNU) using smaller doses of MISO
which did not affect body temperature.
The decomposition of MEL in plasma by
hydrolysis has been shown to be extremely
temperature dependent (Evans et al., 1982), We
measured minimal hydrolysis of MEL in mouse
plasma in vitro at 29°C, whereas at 37°C the half-
life due to hydrolysis was 210min (Hinchliffe &
Stratford, unpublished observations). The plasma
clearance of MEL in vivo occurs with a half-life of
21 min (Figure l(a)) and we have calculated that
even if hydrolysis was completely arrested due to
the reduction in body temperature caused by
MISO, the half-life would only be increased by
2min, whereas a half life of 34min was observed
when MISO was given 60min before MEL. Clearly,
changes in hydrolysis can only account for a small
component of the changed MEL pharmacokinetics
due to MISO.
These results suggest that reduction in body
temperature can only partially account for the
changes in MEL pharmacokinetics observed in
combination with MISO. It was not possible to
determine the effect of MISO on CY pharmaco-
kinetics in mice held at 37°C, nevertheless we
believe the same conclusion is probably true.
Metabolic inhibition
Workman et al. (1983) have shown that MISO
inhibits hepatic drug-metabolising enzymes. MISO
is itself metabolised by these enzymes to form
desmethyl misonidazole (Ro-05-9963) (Shoemaker
et al., 1982). They have, therefore, suggested that
MISO may delay the clearance of chemotherapeutic
drugs by competitively inhibiting their metabolism
(Workman et al., 1983; Lee & Workman, 1983).
This is supported by their findings that the
cytotoxic action of CCNU and chlorambucil can be
potentiated by inhibiting their metabolism with the
drug SKF 525A (Workman & Twentyman, 1982).
The anaesthetics Saffan and Sagatal have also been
found to potentiate tumour cell killing by MEL
(Peacock & Stephens, 1978; Peacock et al., 1980).
These agents are unrelated to MISO but are also
metabolised by liver microsomal enzymes. The
effect was unrelated to a-, body temperature
reduction due to these drugs as the mice were
maintained at 37°C.
The nitroimidazole radiosensitizer SR-2508 is
metab4ised to a much smaller extent than MISO in
the mouse and does not reduce the body
temperature (Workman & Brown, 1981). We have
found that a dose of 5mmolkg-' SR-2508 does
not affect the plasma half-life of MEL (Figure 6)
and does not potentiate the action of MEL in the
WHFIB tumour (Hinchliffe, unpublished
observations). This would tend to support the idea
that MISO may act by competitively inhibiting
drug metabolism. However, Law et al. (1981) have
shown that SR-2508 potentiates the action of CY in
the RIF-1 tumour.
In contrast the o-demethylation product of
MISO, Ro-05-9963 is not appreciably metabolised
in the mouse (Workman, 1980). However, we have
found that it increased the plasma half-life of MEL
in WHT mice and potentiated the action of MEL
and CY in the WHFIB tumour (Hinchliffe,
unpublished observations).
Our results indicate that the increase in MEL
area under the curve results from both an extension
of the peak plasma concentration and a subsequent
reduction in the plasma clearance rate. Whilst
metabolic inhibition would explain the delay in
plasma clearance, it cannot so easily explain the
prolonged peak plasma levels obtained. Moreover
there is little evidence that MEL is metabolised to
any appreciable extent (Furner & Brown, 1980;
Evans et al., 1982). As a result we feel that
metabolic inhibition of plasma clearance by MISO
is not a major factor in the case of MEL. The
extension of peak levels would instead tend to
indicate an effect on the initial distribution of the
drug. It is possible that either the initial absorption
of MEL from the peritoneum and/or its subsequent
distribution into tissues may be impeded by MISO,
possibly due to interference with the active
transport of MEL across membranes (Vistica et al.,
1977).
Chronic doses
The use of large single doses of MISO in mice does
not provide an adequate model with which to
predict the effects of combining radio-sensitizers
with chemotherapeutic drugs in the clinic because
the half-life of MISO in man is much longer (- 8h)
than in the mouse (40-120min), and much smaller
doses are used in man. We have attempted to
simulate human pharmacokinetics of MISO by
maintaining a plasma concentration of 100pgml-1
(0.5mM) for 8h. This plasma level is within the
clinical range and is close to that obtained in each
fraction of a 6 fraction regime.
This chronic dose of MISO did not affect the
pharmacokinetics of MEL when the cytotoxic drug
was given at the end of the 8h chronic dose period
(Figure 7). Our tumour results are puzzling in that
they appear to vary according to the method of382 M. HINCHLIFFE et al.
assay. Large enhancement ratios (ERs) were
obtained in the WHFIB tumour for both MEL and
CY when an in vitro excision assay was used;
however, no enhancement was observed using
regrowth delay (McNally et al., 1983) although
there was enhancement of growth delay in another
tumour, SaF. Conflicting results have been
obtained by other investigators using similar dose
regimes. Large tumour ERs have been observed by
Brown & Hirst (1982) in the Rif-l tumour, whereas
Twentyman & Workman (1983) were unable to
demonstrate any enhancement in the same tumour
unless they extended the chronic dose schedule to
16h; also Randhawa (personal communication) has
been unable to demonstrate any enhancement with
a chronic MISO dose in a different tumour.
In view of the variability in results with chronic
MISO doses further studies are required in order to
determine if pharmacokinetic changes are
associated with drug potentiation for chronic MISO
doses, although there are suggestions that
potentiation may occur without a pharmacokinetic
effect in some tumours.
In spite of these variable results in different
tumour systems, our observation that chronic
MISO dosing does not affect MEL pharmokinetics
suggests that in man there should be no effect of
MISO on drug pharmacokinetics. However,
Twentyman & Workman (1983) have suggested that
a 16h chronic MISO dosing schedule is necessary
in the mouse to simulate the human situation. It is
possible that this extended exposure may have an
effect on drug pharmacokinetics.
In conclusion, we have shown that a large single
dose of MISO alters the pharmacokinetics of CY
and MEL in mice. The mechanism for this
pharmacokinetic effect remains unclear, but is
probably in part related to the MISO induced
reduction in body temperature. In the case of CY,
MISO may also act by competitively inhibiting its
metabolism, although this probably does not
happen with MEL. We have found no effect of
chronic low doses of MISO on CY or MEL
pharmacokinetics, suggesting that altered drug
pharmacokinetics may not be important in the
clinical combination of MISO with chemothera-
peutic drugs.
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